BRIEF

on Affluent Medical (isin : FR0013333077)

Affluent Medical Advances with Artus Device for Urinary Incontinence

Affluent Medical has announced promising results for its Artus artificial urinary sphincter, gaining approval for the pivotal phase of clinical trials. The decision follows positive safety outcomes from the pilot phase, where an 87% reduction in urinary leakage was observed. The upcoming pivotal phase will extend to centers in Spain and Italy.

The study involves the innovative Artus device designed for stress urinary incontinence (SUI), which affects over 400 million people worldwide. The pilot phase saw successful implantation in 10 patients, with all devices activated post-surgery. Artus is the first mechanico-electronic sphincter offering minimally invasive treatment.

The global market for related devices is expected to reach $4.3 billion by 2027. Affluent's CEO highlights the device's potential to significantly improve life quality for SUI patients, providing a much-needed alternative to existing treatments.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Affluent Medical news